Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
Boehringer Ingelheim
Argus Health
Queensland Health

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 7,071,158

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,071,158
Title:Antioxidant enhancement of therapy for hyperproliferative conditions
Abstract: A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.
Inventor(s): Chinery; Rebecca (Nashville, TN), Beauchamp; R. Daniel (Nashville, TN), Coffey; Robert J. (Woodside, CA), Medford; Russell M. (Atlanta, GA), Wadzinski; Brian E. (Nashville, TN)
Assignee: Atherogenics, Inc. (Norcross, GA)
Application Number:09/779,086
Patent Claims:see list of patent claims

Details for Patent 7,071,158

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ➤ Sign Up Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01 ➤ Sign Up Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Sign Up Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07 ➤ Sign Up Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Atherogenics, Inc. (Norcross, GA) 2017-07-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Fish and Richardson
Covington
Julphar
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.